Europe – pharmaceutical daily

October 21, 2024 Off

Lindis Biotech gets positive CHMP Opinion for Korjuny in the EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Lindis Biotech’s trifunctional Korjuny (catumaxomab), anti-CD3 x anti-EpCAM antibody (trAb) for the intraperitoneal treatment of malignant ascites (MA) in adults with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy.

October 18, 2024 Off

SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

By Dino Mustafić

SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, today announced that the dosing of participants has commenced in the first clinical study evaluating the company’s most advanced development program SR-878.

October 18, 2024 Off

NVDX3 can address unmet needs of patients with bone defects

By Dino Mustafić

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, today announces positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults.

October 18, 2024 Off

Brenntag celebrates the company’s 150th anniversary in Essen, Germany

By Author

Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in Essen, Germany, where the DAX40 company is headquartered.

October 18, 2024 Off

Hays names new Head of Life Sciences

By Dino Mustafić

Hays, the global workforce solutions and recruitment specialist, has appointed James Nyssen as Global Head of Life Sciences. The global…

October 2, 2024 Off

Owkin, AstraZeneca to develop AI gBRCA pre-screen solution for breast cancer

By Dino Mustafić

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, and AstraZeneca, have teamed up to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitised pathology slides.

October 2, 2024 Off

Ex CEO of Vifor Pharma joins Moderna’s Board of Directors

By Dino Mustafić

Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna’s Board of Directors, effective October 2, 2024.

September 30, 2024 Off

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM

By Dino Mustafić

Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.

September 27, 2024 Off

Affluant Medical reports net loss of €9.4 million in H1 202 as it develops three devices

By Dino Mustafić

Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.

September 26, 2024 Off

Oxford Drug Design gets a share of a £3 million Collaborative Discovery Programme

By Dino Mustafić

Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.